Home » Pfizer Japan Obtains Manufacturing Approval for VFEND Antifungul Agent
Pfizer Japan Obtains Manufacturing Approval for VFEND Antifungul Agent
April 14, 2005
Pfizer Japan announced April 12 that it has received approval to manufacture VFEND, its proprietary antifungul agent, from the Ministry of Health, Labor and Welfare.VFEND, which has a broad antifungul spectrum, is proven effective against Aspergillus, a type of fungus. Pfizer Japan will introduce two preparations, either 50 mg/200 mg tablets or 200 mg injection, in June. The company expects that the new agent VFEND will contribute to the treatment of deep-seated mycosis.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9842)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct